| Literature DB >> 15467431 |
Jason A Sager1, Silvia Benvenuti, Alberto Bardelli.
Abstract
The PRL-3 phosphatase has joined the cancer arena very recently but is rapidly gaining interest both as a putative prognostic factor and as a therapeutic target for metastatic tumors. In this issue Guo and colleagues provide another key piece of information by showing that the catalytic activity of PRL-3 is required for experimental metastasis formation in mouse models. Here we summarize the current knowledge and discuss what remains to be done before PRL-3 could be considered as a target for diagnostics or therapeutics in the clinical setting of human cancer.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15467431 DOI: 10.4161/cbt.3.10.1115
Source DB: PubMed Journal: Cancer Biol Ther ISSN: 1538-4047 Impact factor: 4.742